JP2016512514A - チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法 - Google Patents

チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法 Download PDF

Info

Publication number
JP2016512514A
JP2016512514A JP2016501053A JP2016501053A JP2016512514A JP 2016512514 A JP2016512514 A JP 2016512514A JP 2016501053 A JP2016501053 A JP 2016501053A JP 2016501053 A JP2016501053 A JP 2016501053A JP 2016512514 A JP2016512514 A JP 2016512514A
Authority
JP
Japan
Prior art keywords
alkyl
group
substituted
aromatic
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016501053A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512514A5 (cg-RX-API-DMAC7.html
Inventor
ジョランタ グレンベッカ,
ジョランタ グレンベッカ,
トマス シエルピキ,
トマス シエルピキ,
ドミトリー ボルキン,
ドミトリー ボルキン,
ジェイ ヘス,
ジェイ ヘス,
ドゥシン スン,
ドゥシン スン,
シャオチン リー,
シャオチン リー,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan (System)
Original Assignee
University of Michigan (System)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan (System) filed Critical University of Michigan (System)
Publication of JP2016512514A publication Critical patent/JP2016512514A/ja
Publication of JP2016512514A5 publication Critical patent/JP2016512514A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016501053A 2013-03-13 2014-03-10 チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法 Withdrawn JP2016512514A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361780099P 2013-03-13 2013-03-13
US61/780,099 2013-03-13
PCT/US2014/022750 WO2014164543A1 (en) 2013-03-13 2014-03-10 Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018088243A Division JP6670885B2 (ja) 2013-03-13 2018-05-01 チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法

Publications (2)

Publication Number Publication Date
JP2016512514A true JP2016512514A (ja) 2016-04-28
JP2016512514A5 JP2016512514A5 (cg-RX-API-DMAC7.html) 2017-05-18

Family

ID=51529943

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016501053A Withdrawn JP2016512514A (ja) 2013-03-13 2014-03-10 チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法
JP2018088243A Active JP6670885B2 (ja) 2013-03-13 2018-05-01 チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018088243A Active JP6670885B2 (ja) 2013-03-13 2018-05-01 チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法

Country Status (11)

Country Link
US (4) US9216993B2 (cg-RX-API-DMAC7.html)
EP (1) EP2968342B1 (cg-RX-API-DMAC7.html)
JP (2) JP2016512514A (cg-RX-API-DMAC7.html)
KR (1) KR20150130389A (cg-RX-API-DMAC7.html)
CN (1) CN105188705A (cg-RX-API-DMAC7.html)
AU (1) AU2014249233A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015022602A2 (cg-RX-API-DMAC7.html)
CA (1) CA2904612A1 (cg-RX-API-DMAC7.html)
IL (1) IL241193A0 (cg-RX-API-DMAC7.html)
MX (1) MX2015011576A (cg-RX-API-DMAC7.html)
WO (1) WO2014164543A1 (cg-RX-API-DMAC7.html)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019517548A (ja) * 2016-06-10 2019-06-24 ヴァイティー ファーマシューティカルズ,エルエルシー メニン−mll相互作用の阻害剤
WO2019189732A1 (ja) * 2018-03-30 2019-10-03 大日本住友製薬株式会社 光学活性な架橋型環状2級アミン誘導体
JP2019530745A (ja) * 2016-09-14 2019-10-24 ヤンセン ファーマシューティカ エヌ.ベー. メニン−mll相互作用の縮合二環式阻害剤
JP2019532100A (ja) * 2016-09-14 2019-11-07 ヤンセン ファーマシューティカ エヌ.ベー. メニン−mll相互作用のスピロ二環式阻害剤
JP2020514388A (ja) * 2017-03-24 2020-05-21 クラ オンコロジー,インク. 血液悪性腫瘍およびユーイング肉腫を処置するための方法
JP2021506882A (ja) * 2017-12-20 2021-02-22 ヤンセン ファーマシューティカ エヌ.ベー. メニン−mll相互作用のエキソ−アザスピロ阻害剤
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
US11530226B2 (en) 2016-12-15 2022-12-20 Janssen Pharmaceutica Nv Azepane inhibitors of menin-MLL interaction
JP2023512113A (ja) * 2019-11-29 2023-03-23 大鵬薬品工業株式会社 Kras g12d変異に対して阻害活性を有する化合物
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
JP2025501287A (ja) * 2021-12-31 2025-01-17 成都先▲導▼▲薬▼物▲開▼▲発▼股▲フン▼有限公司 Menin阻害剤及びその用途
US12473295B2 (en) 2019-12-19 2025-11-18 Janssen Pharmaceutica Nv Substituted straight chain spiro derivatives

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6535430B2 (ja) * 2012-09-28 2019-06-26 イグニタ、インク. 非定型プロテインキナーゼcのアザキナゾリン阻害薬
AU2014249233A1 (en) 2013-03-13 2015-09-24 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
US10526341B2 (en) * 2014-11-19 2020-01-07 Memorial Sloan-Kettering Cancer Center Thienopyrimidines and uses thereof
WO2016197027A1 (en) * 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
TWI703150B (zh) * 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制menin及mll蛋白之交互作用的方法及組合物
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
AU2017212572A1 (en) * 2016-01-26 2018-08-23 Memorial Sloan-Kettering Cancer Center Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
US10752639B2 (en) 2016-03-16 2020-08-25 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-MLL and methods of use
WO2017161028A1 (en) * 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
CN109415337B (zh) 2016-05-02 2022-01-18 密执安大学评议会 作为多发性内分泌腺瘤蛋白抑制剂的哌啶
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
CA3033239A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
EA039109B1 (ru) * 2016-12-07 2021-12-06 Кура Онколоджи, Инк. Мостиковые бициклические ингибиторы взаимодействия менин-mll и способы применения
EA201991448A1 (ru) 2017-01-06 2019-12-30 Янссен Фармацевтика Нв Азепановые ингибиторы взаимодействия менин-mll
EA038388B1 (ru) * 2017-01-16 2021-08-19 Кура Онколоджи, Инк. Замещенные ингибиторы менина-mll и способы применения
EP3600313A4 (en) 2017-03-31 2020-09-23 The Regents of The University of Michigan PIPERIDINES AS COVALENT MENINE INHIBITORS
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
TW201920170A (zh) * 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
CN110204552B (zh) * 2018-02-28 2021-08-17 中国科学院上海药物研究所 一类噻吩并[3,2-d]嘧啶衍生物、其制备方法、药物组合物与用途
CR20200464A (es) 2018-03-08 2021-04-14 Incyte Corp Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
US12662494B2 (en) 2018-08-08 2026-06-23 Sumitomo Pharma Co., Ltd. Optically active bridged piperidine derivative
EP3860978A1 (en) 2018-10-03 2021-08-11 The Regents Of The University Of Michigan Small molecule menin inhibitors
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
CA3116141C (en) * 2018-12-06 2023-09-05 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2
ES2991429T3 (es) * 2019-02-01 2024-12-03 Univ South Carolina Compuestos de piridina bicíclicos para su uso en el tratamiento del cáncer
BR112021024108A2 (pt) 2019-05-31 2022-03-22 Ikena Oncology Inc Inibidores de tead e usos dos mesmos
US11458149B1 (en) 2019-05-31 2022-10-04 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
CN112116960B (zh) * 2019-06-20 2024-10-11 中国石油化工股份有限公司 柴油加氢反应的组分含量确定方法、装置
TW202126636A (zh) 2019-09-30 2021-07-16 美商阿吉歐斯製藥公司 作為menin抑制劑之六氫吡啶化合物
MD4051678T2 (en) 2019-10-28 2026-07-31 Merck Sharp & Dohme Llc Small molecule inhibitors of the KRAS G12C mutant
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
CN111297863B (zh) * 2020-03-30 2021-06-25 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
IL297039A (en) 2020-04-07 2022-12-01 Syndax Pharmaceuticals Inc Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof
WO2021204159A1 (en) 2020-04-08 2021-10-14 Agios Pharmaceuticals, Inc. Menin inhibitors and methods of use for treating cancer
TW202204334A (zh) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin抑制劑及治療癌症之使用方法
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
AR122159A1 (es) * 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
EP4232020A4 (en) * 2020-10-21 2024-08-07 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin
WO2022109487A1 (en) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
BR112023021040A2 (pt) 2021-05-08 2024-02-06 Janssen Pharmaceutica Nv Derivados espiro substituídos
EP4334310A1 (en) 2021-05-08 2024-03-13 JANSSEN Pharmaceutica NV Substituted spiro derivatives
AR125866A1 (es) 2021-05-14 2023-08-23 Syndax Pharmaceuticals Inc Inhibidores de la interacción de menina-mll
CA3218479A1 (en) 2021-06-01 2022-12-08 Wei Cai Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives
WO2022253289A1 (en) 2021-06-03 2022-12-08 Janssen Pharmaceutica Nv Pyridazines or 1,2,4-triazines substituted by spirocyclic amines
AU2022292697A1 (en) 2021-06-17 2024-02-01 Janssen Pharmaceutica Nv (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
WO2023011446A1 (zh) * 2021-08-04 2023-02-09 成都苑东生物制药股份有限公司 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
WO2023056589A1 (en) 2021-10-08 2023-04-13 Servier Pharmaceuticals Llc Menin inhibitors and methods of use for treating cancer
WO2023215354A1 (en) * 2022-05-03 2023-11-09 Board Of Regents, The University Of Texas System Menin proteolysis targeting chimeras (protacs)
US20260151399A1 (en) 2022-11-24 2026-06-04 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
CN116199633B (zh) * 2022-12-27 2024-05-31 甘肃省化工研究院有限责任公司 一种制备瑞维鲁胺的方法
AR132185A1 (es) 2023-03-24 2025-06-04 Acerta Pharma Bv COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA
KR20260096846A (ko) 2023-10-20 2026-06-24 머크 샤프 앤드 돔 엘엘씨 Kras 단백질의 소분자 억제제

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503906A (ja) * 2009-09-04 2013-02-04 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 白血病を治療するための組成物および方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
EP1947103A1 (en) 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
AR073739A1 (es) * 2008-09-10 2010-12-01 Kalypsys Inc Aminopirimidinas como inhibidores de los receptores de histamina
WO2011014128A1 (en) * 2009-07-30 2011-02-03 National University Of Singapore Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity
GB201114212D0 (en) 2011-08-18 2011-10-05 Ucb Pharma Sa Therapeutic agents
AU2014249233A1 (en) 2013-03-13 2015-09-24 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503906A (ja) * 2009-09-04 2013-02-04 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 白血病を治療するための組成物および方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 120, no. 23, JPN6017045378, 2012, pages 4461 - 4469, ISSN: 0003689140 *
NATURE CHEMICAL BIOLOGY, vol. 8, no. 3, JPN6017045377, 2012, pages 277 - 284, ISSN: 0003689139 *

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7461390B2 (ja) 2016-06-10 2024-04-03 ヴァイティー ファーマシューティカルズ,エルエルシー メニン-mll相互作用の阻害剤
JP2024045176A (ja) * 2016-06-10 2024-04-02 ヴァイティー ファーマシューティカルズ,エルエルシー メニン-mll相互作用の阻害剤
JP2019517548A (ja) * 2016-06-10 2019-06-24 ヴァイティー ファーマシューティカルズ,エルエルシー メニン−mll相互作用の阻害剤
JP2022058514A (ja) * 2016-06-10 2022-04-12 ヴァイティー ファーマシューティカルズ,エルエルシー メニン-mll相互作用の阻害剤
JP7007302B2 (ja) 2016-06-10 2022-01-24 ヴァイティー ファーマシューティカルズ,エルエルシー メニン-mll相互作用の阻害剤
JP7033141B2 (ja) 2016-09-14 2022-03-09 ヤンセン ファーマシューティカ エヌ.ベー. メニン-mll相互作用の縮合二環式阻害剤
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
JP2019530745A (ja) * 2016-09-14 2019-10-24 ヤンセン ファーマシューティカ エヌ.ベー. メニン−mll相互作用の縮合二環式阻害剤
JP2019532100A (ja) * 2016-09-14 2019-11-07 ヤンセン ファーマシューティカ エヌ.ベー. メニン−mll相互作用のスピロ二環式阻害剤
US11220517B2 (en) 2016-09-14 2022-01-11 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
US11530226B2 (en) 2016-12-15 2022-12-20 Janssen Pharmaceutica Nv Azepane inhibitors of menin-MLL interaction
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
JP7749608B2 (ja) 2017-03-24 2025-10-06 クラ オンコロジー,インク. 血液悪性腫瘍およびユーイング肉腫を処置するための方法
JP2025098022A (ja) * 2017-03-24 2025-07-01 クラ オンコロジー,インク. 血液悪性腫瘍およびユーイング肉腫を処置するための方法
JP7628392B2 (ja) 2017-03-24 2025-02-10 クラ オンコロジー,インク. 血液悪性腫瘍およびユーイング肉腫を処置するための方法
JP2023055735A (ja) * 2017-03-24 2023-04-18 クラ オンコロジー,インク. 血液悪性腫瘍およびユーイング肉腫を処置するための方法
JP2020514388A (ja) * 2017-03-24 2020-05-21 クラ オンコロジー,インク. 血液悪性腫瘍およびユーイング肉腫を処置するための方法
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
JP2021506882A (ja) * 2017-12-20 2021-02-22 ヤンセン ファーマシューティカ エヌ.ベー. メニン−mll相互作用のエキソ−アザスピロ阻害剤
JP7307729B2 (ja) 2017-12-20 2023-07-12 ヤンセン ファーマシューティカ エヌ.ベー. メニン-mll相互作用のエキソ-アザスピロ阻害剤
CN112105621A (zh) * 2018-03-30 2020-12-18 大日本住友制药株式会社 光学活性桥型环状仲胺衍生物
JPWO2019189732A1 (ja) * 2018-03-30 2021-04-08 大日本住友製薬株式会社 光学活性な架橋型環状2級アミン誘導体
CN112105621B (zh) * 2018-03-30 2024-02-20 住友制药株式会社 光学活性桥型环状仲胺衍生物
WO2019189732A1 (ja) * 2018-03-30 2019-10-03 大日本住友製薬株式会社 光学活性な架橋型環状2級アミン誘導体
JP7239562B2 (ja) 2018-03-30 2023-03-14 住友ファーマ株式会社 光学活性な架橋型環状2級アミン誘導体
US11325921B2 (en) 2018-03-30 2022-05-10 Sumitomo Dainippon Pharma Co., Ltd. Optically active crosslinked cyclic secondary amine derivative
JP2023512113A (ja) * 2019-11-29 2023-03-23 大鵬薬品工業株式会社 Kras g12d変異に対して阻害活性を有する化合物
JP7707189B2 (ja) 2019-11-29 2025-07-14 大鵬薬品工業株式会社 Kras g12d変異に対して阻害活性を有する化合物
US12473295B2 (en) 2019-12-19 2025-11-18 Janssen Pharmaceutica Nv Substituted straight chain spiro derivatives
JP2025501287A (ja) * 2021-12-31 2025-01-17 成都先▲導▼▲薬▼物▲開▼▲発▼股▲フン▼有限公司 Menin阻害剤及びその用途
JP7833041B2 (ja) 2021-12-31 2026-03-18 成都先▲導▼▲薬▼物▲開▼▲発▼股▲フン▼有限公司 Menin阻害剤及びその用途

Also Published As

Publication number Publication date
IL241193A0 (en) 2015-11-30
WO2014164543A1 (en) 2014-10-09
US20170253611A1 (en) 2017-09-07
KR20150130389A (ko) 2015-11-23
US9216993B2 (en) 2015-12-22
US20160137665A1 (en) 2016-05-19
EP2968342A1 (en) 2016-01-20
JP2018115214A (ja) 2018-07-26
US9505782B2 (en) 2016-11-29
BR112015022602A2 (pt) 2017-07-18
EP2968342A4 (en) 2016-07-27
EP2968342B1 (en) 2018-10-03
JP6670885B2 (ja) 2020-03-25
US9505781B2 (en) 2016-11-29
CA2904612A1 (en) 2014-10-09
US10160769B2 (en) 2018-12-25
US20140275070A1 (en) 2014-09-18
US20160046647A1 (en) 2016-02-18
AU2014249233A1 (en) 2015-09-24
MX2015011576A (es) 2016-05-16
CN105188705A (zh) 2015-12-23

Similar Documents

Publication Publication Date Title
JP6670885B2 (ja) チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法
AU2020203464B2 (en) Sulfonylureas and related compounds and use of same
CN113811300B (zh) Tead转录因子的新型小分子抑制剂
JP6759514B2 (ja) ブロモドメインに対して活性な化合物
ES2398606T3 (es) Derivados de 2-piridin-carboxamida como moduladores de los canales de sodio
ES2534227T3 (es) Derivados de 4-aminopirimidina y su uso como antagonistas del receptor A2A de adenosina
BR112020026748A2 (pt) Inibidores de quinases dependentes de ciclina
ES2351110T3 (es) Compuestos de piperidinilamino-tieno[2,3-d]-pirimidina.
JP4173191B2 (ja) H3リガンドとして有用な3‐または4‐一置換フェノールおよびチオフェノール誘導体
RS63603B1 (sr) Sredstva za indukciju apoptoze
AU2014400628A1 (en) Aminopyridazinone compounds as protein kinase inhibitors
JP2008514643A (ja) 新規ピペリジニルアミノ−チエノ[2,3−d]ピリミジン化合物
CA3198096A1 (en) Aryl derivatives for treating trpm3 mediated disorders
AU2017327304B2 (en) Use of morphinan derivative for therapeutic treatment of opioid δ receptor agonist-related disease
BR112020019399A2 (pt) Compostos macrocíclicos como inibidores de trk quinases
CA2979758A1 (en) New fyn kinase inhibitors
KR20130005263A (ko) 치환된 나프탈레닐-피리미딘 화합물
AU2022345092A1 (en) Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof
CN106986832A (zh) Vegfr3抑制剂
JP2024540264A (ja) ゴナドトロピン放出ホルモン拮抗剤及びその調製方法並びに使用
WO2021000957A1 (zh) 一种杂环化合物、其药物组合物及用途
BR112017017610B1 (pt) Composto de fórmula (ii) ou um sal ou solvato farmaceuticamente a c e i t á v e i s d o m e s m o , u s o d o c o m p o s t o o u d o s a l o u s o l v a t o farmaceuticamente aceitáveis e composição farmacêutica

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180227

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20180522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180611